Home > Boards > US OTC > Medical - Equipment >

Zenosense, Inc. (ZENO)

Add ZENO Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 1/19/2019 12:17:21 AM - Followers: 37 - Board type: Free - Posts Today: 1

NEWS JUNE17! Yahoo Finance: Zenosense, Inc. ( OTC PINK : ZENO ) has received notice of a patent issuance in the U.S.

YTD: 266%
1 Year: 141%


ZenoSense (OTC:ZENO) has carved out a unique space in a revolutionary new biomedical field that is forecast to grow to $7.2 billion in the next year. ZENO is on the vanguard of this rapid growth because it’s focusing on a disease that claims the lives of 1 in 4 Americans.(1)

About Zenosense
The Revolution In Cardiac Diagnostics

Laboratory accuracy testing in the palm of your hand -
Taking diagnosis to a new, super-sensitive, nano-magnetic level

Zenosense, Inc. (OTC:ZENO) participates in the development of transformational medical diagnostic technologies: hand-held devices used at the Point of Care replacing slow and expensive laboratory testing. Our core focus through our joint venture in MIDS Medical (http://midsmed.com/) is the development and commercialisation of MIDS Cardiac™. A hand held device being developed for use at the Point of Care for the rapid testing of cardiac markers delivering results equal or superior to laboratory gold standard accuracy within minutes. A device which can revolutionize the diagnosis and management of suspected Acute Myocardial Infarction (AMI).

Our team of professionals has world class expertise and technical know-how of the application of highly specific nano magnetic particle technology to medical testing.  This knowledge, alongside their commercial experience of the Point of Care market, puts MIDS Medical in an excellent position to commercialise MIDS Cardiac™ and become the leading innovator in this field.

The MIDS Medical laboratory is located at the prestigious, UK Government supported Sci-Tech Daresbury campus in the UK. Sci-Tech Daresbury is internationally recognised for leading-edge scientific research and commercial development.

Good to know
Cardiovascular disease is the leading cause of death in the Western World. Accounting for more than 17 million deaths p.a. In Europe and the US alone approximately 15-20 million patients a year visit an Emergency Department (ED) reporting chest pain which must be investigated as possibly caused by a cardiac event. Every 43 seconds someone in the US has a heart attack.

Acute Myocardial Infarction (heart attack, Acute Myocardial Infraction “AMI”) affects all of us at some point in our lives, directly or indirectly, Rapid diagnosis is key; treatment in the first “Golden Hour” being crucial to survival. Equally, early “rule out” of AMI as  the cause of chest pain can save healthcare providers $billions.

Through our Joint Venture ownership in MIDS Medical we are developing MIDS Cardiac™, a cost-effective hand held Point of Care rapid cardiac diagnostic device. MIDS Medical applies patent-protected magnetic nanoparticle detection technology and world-class technical expertise.

Our development targets the delivery of a hand held device to support high sensitivity tests to identify or discount AMI (Heart Attack), with accuracy equal or better than gold standard laboratory tests, within minutes. This will significantly accelerate the triage, diagnosis, treatment and disposition of patients reporting chest pain and with suspected Acute Myocardial Infarction.

The system is designed to be used with a minimum of training; by any ER nurse or by paramedics at the scene. We believe such a device will be in universal demand; able to meet a critical medical need and rapidly penetrate a multi-billion dollar market.

MIDS Cardiac(TM)
Rapid detection of very low levels of cardiac markers with a primary focus on troponin I and T, designed to equal or exceed gold standard laboratory levels of accuracy, at the Point of Care.

>> Proof of Market (PDF) <<

Investment Highlights

  • Addressing Lethal Global Health Threat
    Co-Developing Unique Detection Device
    Strong Partnership with Sgenia Group
    Experienced, Strong Management
    Team of Highly Qualified Biologists

Key Partnership

Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through its subsidiary, Zenon Biosystem. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors." The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.

Sgenia Group, known for sensor development and a supplier of sensors used in the Tokamak device for a significant, international nuclear fusion research project, also produces an algal contamination detector for use in water supply applications. It rapidly and effectively scans for the volatile organic compounds (VOCs) emitted by the target algae, a unique “chemical signature” that determines the presence or absence of the algae. The Sgenia detector is effectively an electronic “nose” that can smell this signature.

Zenon is using essential elements of these technology platforms in a development program for the MRSA/SA device to be developed for Zenosense.


Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors.

Carlos Jose Gil, BSc (Engineering) - President, CEO, CFO

Carlos Jose Gil joined the company in October 2013 as a member of the board. He has experience in high-level sales management and the development of sales teams in the health care sector. From 2012 to 2013, Gil served as a managing director of Porsche Car Spain. From 2009 to 2012, Gil was sales manager at Pharmaceutic Laboratory PersanFarma. From 1994 to 2009, Gil was a medical consultant in Medical Affairs and then an account manager at Pharmaceutic Laboratory Janssen-Cilag (Johnson & Johnson). Gil holds a Bachelor of Science in Chemical Science from Valencia University, Spain.

Development Team

J. Lama, MBA, BSc

J. Lama is an engineer with a Master of Business Administration and a Bachelor of Science (Physics). His experience includes material engineering, solid state physics, electronics, renewable energy, the automotive industry and developing technological business.

M. Querol, MS

M. Querol is a mechanical engineer with a Master of Science in Telecommunications Engineering. His experience includes market development of global solutions for Aeronautical, Naval and Defense sectors, market development of internalization strategy development, and market development of industrial engineering solutions.

M. I. Gil, DEA, BSc

M. I. Gil has a Master of Advanced Studies in Fluids Mechanics from Centro Politecnico Superior of University of Zaragoza in Spain, as well as a Bachelor of Telecommunication Engineering. Gil has wide experience in sensor technologies and advanced technical and software developing.

G. Roman Perez, PhD, MAS, BSc

G. Roman Perez has a PhD in physics from the Autonomous University of Madrid (UAM), with Cum Laude distinction. He also has a Master of Advanced Studies in Condensed Matter Physics, a Master of Biophysics and a Bachelor of Physics, all issued by UAM. His work has been published in several different publications and he has spoken at conferences in France, Italy, Spain and the USA.


The company will also rely upon a team of three biologists contracted to Zenon for the development of the Sgenia Products. This team is comprised of molecular biologists and biochemists specializing in bacterial physiology and genetics, clinical microbiology and molecular biology. All hold relevant PhDs, and two hold Masters, in disciplines highly relevant to optimizing the company’s sensor for the detection of MRSA/SA. The team’s combined skillset includes deep knowledge of the clinical genetics to be addressed in order to program and refine the sensor so that it can detect SA and ideally discriminate between MRSA and SA. Variously, members of the team are business (biotechnology) management qualified, have co-authored numerous scientific publications, taught as professor, have experience of the practical clinical setting in hospital and have co-invented patents for others.

Zenosense, Inc.
Avda Cortes Valencianas 58
Planta 5 46015
Valencia, Spain
Phone: 34-96-045-4202


QualityStocks designed this iBox. Please see disclaimers on the QualityStocks website: http://qualitystocks.net/disclaimer.php

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ZENO News: Quarterly Report (10-q) 11/14/2018 05:13:15 PM
ZENO News: Zenosense, Inc.: MIDS Medical Expands Technical Team 10/02/2018 07:42:11 AM
ZENO News: Zenosense, Inc.: MIDS Medical JV to Receive Funding of Up to $1.2 Million 09/05/2018 08:00:44 AM
ZENO News: Current Report Filing (8-k) 09/04/2018 05:14:08 PM
ZENO News: Quarterly Report (10-q) 08/20/2018 04:59:59 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#1239   Been to Daresbury. You? derkampfer 01/19/19 12:17:21 AM
#1238   You sure? Did you visit their office ?? Hehe Las_Vegas 01/18/19 01:03:41 AM
#1237   It’s not a pump. They make good progress derkampfer 01/11/19 03:34:30 PM
#1236   Sleeping before the next move? Seems like the AW104 01/11/19 01:56:22 PM
#1235   Yeah but being mentioned in a complaint vs AW104 11/01/18 10:23:55 PM
#1234   Thats because ZENO is mentioned in an SEC elkonig 11/01/18 05:24:04 PM
#1233   Volume dropping 0 this morning. Low volume=low interest. lt2211 10/24/18 09:45:14 AM
#1232   Maybe it’ll hit tomorrow? Seems like we’re trading AW104 10/02/18 10:33:57 PM
#1231   NEWS OUT! Zenosense, Inc.: MIDS Medical Expands Technical Team hotstockpicker 10/02/18 08:27:05 AM
#1230   Any word on what’s happening here? Seems like AW104 09/20/18 11:10:00 PM
#1229   Soon to be saving lives and selling DOLLARS ! GrabThatCash 09/05/18 05:06:28 PM
#1228   Buying pennies he he Stockteacher80 09/05/18 04:09:10 PM
#1227   Don’t worry about nnsr just continue to buy Stockteacher80 09/05/18 04:02:17 PM
#1226   Haha news and she drops. No market manipulation AW104 09/05/18 12:49:35 PM
#1225   Curious how high this will go. Back to AW104 09/05/18 09:24:19 AM
#1224   NEWS OUT! https://finance.yahoo.com/news/zenosense-inc-mids-medical-jv-113000422 hotstockpicker 09/05/18 08:05:58 AM
#1223   And Jordan Belford Las_Vegas 09/04/18 05:00:58 PM
#1222   Where is Tim Sykes to pump this shix Las_Vegas 07/30/18 04:45:51 PM
#1221   Yeah they got a great potential idea to Las_Vegas 07/30/18 04:44:58 PM
#1220   This is early heart attack detection. Potentially saving derkampfer 07/30/18 01:42:12 AM
#1219   No progress?! Tom Barr of Bio-AMD and U.K. team derkampfer 07/30/18 01:38:53 AM
#1218   They have been worked on this for last Las_Vegas 07/30/18 12:21:00 AM
#1217   It was pump and dump by group of Las_Vegas 07/30/18 12:20:09 AM
#1216   Also got Zacks email this AM with same derkampfer 07/18/18 01:04:25 AM
#1215   I guess I woke up whoever was on stockmule 07/17/18 10:59:45 AM
#1214   I haven't read it but find it interesting stockmule 07/17/18 09:32:51 AM
#1213   Nice Zacks article this AM on Zenosense. Apparently derkampfer 07/17/18 01:13:47 AM
#1212   Zenosense Trading on the OTCQB Venture Market hotstockpicker 07/10/18 08:29:26 AM
#1211   The stock went to $4+ on a fraction derkampfer 07/06/18 05:17:58 PM
#1210   $10/share lol AW104 07/06/18 03:29:29 PM
#1209   What value would you place on a company derkampfer 07/06/18 11:03:15 AM
#1208   ZENO. settled in the 40's until the next subslover 06/27/18 10:11:28 AM
#1207   Nice bounce. willlbone 06/22/18 11:08:22 AM
#1206   That’s a great position to start at. I AW104 06/21/18 03:27:50 PM
#1205   Got a starter at 30 cents. willlbone 06/21/18 02:08:02 PM
#1204   Figured we would have seen a run that AW104 06/21/18 11:45:11 AM
#1203   Get in now ! http://www.newbiotechstock.com/new/zeno/invest/mobile/?utm_source= GrabThatCash 06/20/18 12:54:51 PM
#1202   Profits are taken, up we go! AW104 06/20/18 10:57:32 AM
#1201   No sweat, this is GREAT NEWS ! GrabThatCash 06/20/18 09:34:07 AM
#1200   yes i am off on my numbers sorry.. McMagyar 06/20/18 09:23:37 AM
#1199   Please ignore previous message..NEW NUMBERS.. McMagyar 06/20/18 08:45:20 AM
#1198   McM. Interesting analysis. Not sure if profit of derkampfer 06/20/18 08:39:29 AM
#1197   the MIDS team is impressive..nice partner.. McMagyar 06/20/18 07:56:40 AM
#1196   an amazing 5 posts here today.. McMagyar 06/19/18 11:53:00 PM
#1195   NOT a steaming pile ! Long and GrabThatCash 06/19/18 04:34:08 PM
#1194   ZENO up 101.5% in one trading day! Now subslover 06/19/18 04:02:11 PM
#1193   Hello ZENO!! https://globenewswire.com/news-release/2018/06/19/1526362/0/en/Zen AW104 06/19/18 03:41:16 PM
#1192   “The MIDS LoD of both these brands was derkampfer 06/19/18 09:08:22 AM
#1191   Zenosense, Inc.: Breakthrough Quantitative MIDS Testing Results subslover 06/19/18 08:18:40 AM
#1190   Nope just pointing out that this is a sandman44 06/04/18 10:40:40 AM